Editas Medicine, Inc. (EDIT) News
Filter EDIT News Items
EDIT News Results
|Loading, please wait...|
EDIT News Highlights
- EDIT's 30 day story count now stands at 34.
- Over the past 26 days, the trend for EDIT's stories per day has been choppy and unclear. It has oscillated between 1 and 6.
- GENE, IPSC and STEM are the most mentioned tickers in articles about EDIT.
Latest EDIT News From Around the Web
Below are the latest news stories about EDITAS MEDICINE INC that investors may wish to consider to help them evaluate EDIT as an investment opportunity.
In stock investing, it's easy to focus on big names and blue-chip companies since they are frequently reported in financial media. Conversely, smaller companies, but with promising businesses, tend to be ignored. Three such businesses in the pharma and biotech industries are Ironwood Pharmaceuticals (NASDAQ: IRWD), Exelixis (NASDAQ: EXEL), and Editas Medicine (NASDAQ: EDIT).
Let us look at some biotech stocks, ALLO, EDIT, NTLA and SGEN that are poised to beat on fourth-quarter earnings.
Shares of Editas Medicine (NASDAQ: EDIT) were up 21.1% for the week as of Friday morning, according to data provided by S&P Global Market Intelligence. Investors clearly are in favor of the company's moves to strengthen its cash position and long-term prospects. The science that Editas Medicine uses has shown tremendous potential.
Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
With shares down by 60% in the last three years, Editas Medicine (NASDAQ: EDIT) investors are experiencing a bumpy ride despite the company's impeccable gene-editing credentials. Hitting a home run in clinical trials could be enough to revitalize the buzz around its innovative gene-editing platform. Perhaps the best argument against buying Editas stock is that its drug development pipeline is about to be rendered much less lucrative thanks to a competitor.
CRISPR stocks are heating back up after a difficult 2022.
The genome-editing company's shares spiked following a definitive agreement with Shoreline Biosciences last month.
Cantor Fitzgerald initiated coverage on Editas Medicine Inc (NASDAQ: EDIT) with an Overweight rating and a price target of $15. The analyst says that following the recent pipeline reprioritization and pausing of internal investments in the retinal disease/induced pluripotent stem cell-derived natural killer cell programs, Editas shares are well-positioned to appreciate in the coming year due to favorable IP positioning and expected clinical data updates. Also See: Citing Small Population, Editas
CRISPR stocks are becoming commercially viable leading to substantial returns in 2023 and beyond, as the technology will only improve.
CRISPR technology has the potential to revolutionize the way we approach medicine. This technology has already been used in a variety of applications, including gene editing, gene therapy, and disease diagnosis. As a result, companies developing CRISPR-based products and services have seen significant valuation growth since inception, with many CRISPR stocks having excellent long-term upside potential in this regard. Several companies at the forefront of CRISPR technology have seen their stocks